American Heart Journal
Volume 152, Issue 4 , Pages 684.e1-684.e9 , October 2006

Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: Findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS

  • Peter R. Sinnaeve, MD, PhD

      Affiliations

    • Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium
    • Corresponding Author InformationReprint requests: Peter R. Sinnaeve, MD, PhD, Department of Cardiology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
    • ,
  • Yao Huang, PhD

      Affiliations

    • Duke Clinical Research Center, Durham, NC
    • ,
  • Kris Bogaerts, PhD

      Affiliations

    • Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Alec Vahanian, MD, PhD

      Affiliations

    • Cardiology Department, Bichat Hospital, Paris, France
    • ,
  • Jennifer Adgey, MD, PhD

      Affiliations

    • Regional Medical Cardiology Centre, Royal Victoria Hospital, Belfast, Northern Ireland
    • ,
  • Paul W. Armstrong, MD

      Affiliations

    • Department of Cardiology, University of Alberta, Edmonton, Canada
    • ,
  • Lars Wallentin, MD

      Affiliations

    • Department of Cardiology University Hospital, Uppsala, Sweden
    • ,
  • Frans J. Van de Werf, MD, PhD

      Affiliations

    • Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Christopher B. Granger, MD

      Affiliations

    • Duke Clinical Research Center, Durham, NC
    • ,
  • on behalf of the ASSENT-3 and ASSENT-3 PLUS investigators

Received 5 October 2005 ,Accepted 3 July 2006.

  • Image Result

    Design and therapies in ASSENT-3 and ASSENT-3 PLUS.

    Design and therapies in ASSENT-3 and ASSENT-3 PLUS.

  • Image Result

    A, Risk ratios and 95% CI for the risk composite efficacy end point (death, reinfarction, and refractory angina), and efficacy and safety end point (efficacy plus ICH and noncerebral major bleeding co

    A, Risk ratios and 95% CI for the risk composite efficacy end point (death, reinfarction, and refractory angina), and efficacy and safety end point (efficacy plus ICH and noncerebral major bleeding complications) in patients treated with enoxaparin versus UFH. B, Risk ratios and 95% CI for the risk composite efficacy end point (death, reinfarction, and refractory angina), and efficacy and safety end point (efficacy plus ICH and noncerebral major bleeding complications) in patients treated with abciximab versus UFH (results from ASSENT-3 and ASSENT-3 PLUS).

  • Image Result
    Composite efficacy (panel A) and efficacy plus safety (panel B) end points as a function of age.

    Composite efficacy (panel A) and efficacy plus safety (panel B) end points as a function of age.

PII: S0002-8703(06)00631-4

doi: 10.1016/j.ahj.2006.07.005

American Heart Journal
Volume 152, Issue 4 , Pages 684.e1-684.e9 , October 2006

Article Tools

* Image Usage & Resolution